PM
LGND icon

Pembroke Management’s Ligand Pharmaceuticals LGND Stock Holding History

Pembroke Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
+40,277
New +$9.49M 1.65% 24

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pembroke Management's LGND Position: Q2 2026 in Review

Pembroke Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 40,277 shares worth $12.7M. The stake represents 1.65% of the portfolio and ranks #24 among its holdings.

417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Pembroke Management held 40,277 shares of Ligand Pharmaceuticals worth $12.7M as of Q2 2026.
  • Ligand Pharmaceuticals was a new Pembroke Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 1.65% of Pembroke Management's portfolio in Q2 2026, its #24 holding.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pembroke Management's 13F filing for Q2 2026, filed 22 Jul 2026.